Declining Rates of Cervical Intraepithelial Neoplasia in British Columbia, Canada: An Ecological Analysis On The Effects of The School-Based HPV Vaccination Program
Menée en Colombie Britannique (Canada) à partir de données portant sur les frottis réalisés entre 2004 et 2017 chez les femmes âgées de 16 à 28 ans, cette étude analyse l'effet du programme provincial de vaccination contre le papillomavirus humain sur l'incidence des lésions cervicales intraépithéliales de haut grade (CIN2 et CIN3)
Human Papillomavirus (HPV) is the most common sexually transmitted infection, with a lifetime risk of approximately 80%. Globally, approximately five percent of all cancers can be attributed to HPV. Since licensure of prophylactic vaccines against multiple HPV genotypes, many countries and jurisdictions have implemented HPV vaccination in their routine immunization programs. Three HPV vaccines have been used in public health programs so far: the bivalent HPV vaccine protects against HPV16/18, which are responsible for 70% of cervical cancers, the quadrivalent vaccine which also covers HPV6/11, responsible for 90% of anogenital warts and the nonavalent vaccine which covers five additional high-risk HPV types, HPV31/33/45/52/58, responsible for an approximate additional 20% of cervical cancers.5 In addition, besides high efficacy against the types included in the vaccines, population-based studies have indicated that the bivalent HPV vaccine is effective in the prevention of HPV31/33/45 as well, which is called cross-protection.